background

Neurophyxia's main objective is to develop 2-iminobiotin (or 2-IB) a novel injectable pharmaceutical product to reduce the deleterious effects of oxygen shortage in the brain occurring in two lifethreatening conditions:

  • Cardiac arrest in adult patients, which includes the areas of Out of Hospital Cardiac Arrest (OHCA) and In Hospital Cardiac Arrest (IHCA) 
  • Birth asphyxia, also called perinatal asphyxia in newborn children

The Magnitude of the problems

Cardiac arrest:

  • Over a million patients in the US and the European Union suffer from this condition annualy
  • Despite the introduction of defibrillators, over 70% of the patients die before admission to the hospital
  • 30-50% of survivors have cognitive defects due to oxygen shortage in the brain, especially related to memory and attention

Birth asphyxia:

  • In the Western World: Birth asphyxia is a rare problem in the Western World occurring in 1-3 per 1000 live births (in total around 50-100.000 cases per year in the Western World) The impact is however enormous with an estimated life-time cost of about € 900.000 per person according to the US Centers of Disease Control
  • In low- income countries: Over the past 25 years, the world has made significant progress in saving young children’s lives. But this progress has not been made for rate of newborn deaths. In 2016 alone, 7,000 newborn babies died every day. Most of these deaths are caused by prematurity, complications during labor and birth (24%), and infections (Unicef Child Mortality Report 2017). In low-income countries birth asphyxia is a huge problem, occurring in up to 40 to 1.000 live births and remains responsible for 2.0 % of all cause disability adjusted life years (DALY’s; vizhub.healthdata.org).